Nilotinib, the bcr‐abl kinase inhibitor, was approved for the treatment of imatinib‐resistant chronic myelogenous leukemia, and can induce autophagic cell death in HCC through AMPK activation [21]. Here, PRKAA2 is linked to hepatocellular carcinoma.